In the Neurology and Stroke Unit structure of Arnas Brotzudirected by Giovanni Cossuwas treated the first patientaffected by Parkinsonwith the Levodopa drug for subcutaneous infusion.
The drug is usually taken orally, in the form of capsules or tablets. But Fluctuations in plasma drug concentrations when ingested are often associated with variable control of motor symptoms and to the sdevelopment of involuntary movementsthe. That’s why you are the option of treatment by subcutaneous infusion was evaluatedrecently introduced on the market but whose availability is not yet guaranteed in a large part of the national territory.
To ensure the success of the subcutaneous treatment of Levodopa, eligible patients must be carefully selected by expert centersWhy not all symptoms may be responsive.
«Arnas Brotzu, thanks to the commitment of the company management and the pharmacy service, was one of the first hospitals to introduce this new route of administration which presents a potential advantage in the treatment of the intermediate-advanced phase of Parkinson’s disease – comments Cossu – can guarantee one stable management of symptoms which, due to gastroenterological problems specific to the disease or associated pathologies, cannot be controlled with conventional therapies”.
The hope is that the new therapeutic strategy can improve the quality of life of patients with Parkinson’s disease. “The Initial effects are promising although, for definitive efficacy data, it will be necessary to wait for a longer observation period”, underlines manager Agnese Foddis.
(Unioneonline)
© All rights reserved
Tags: Subcutaneous infusion drug therapy Parkinsons Cagliari
